Hypothalamic alpha 2A-adrenoceptors stimulate growth hormone release in the rat.
Oxymetazoline, the relatively selective alpha 2A-adrenoceptor agonist (with more than 60-fold selectivity over the alpha 2B-adrenoceptor subtype), was administered into the lateral ventricle (i.c.v.) of rats and plasma growth hormone (GH) levels were measured. Oxymetazoline was more potent to release GH after i.c.v. administration than was clonidine; 0.01 microgram i.c.v. oxymetazoline already caused a significant release of GH, while at least 0.1 microgram clonidine had to be administered to cause a similar response. The dose-response curve was of an inverted U shape since with 10 micrograms of oxymetazoline the plasma GH did not rise. When oxymetazoline was injected i.c.v. to rats with somatostatin fibres to the median eminence transected by an anterolateral cut in the hypothalamus there was a significant rise in plasma GH, suggesting that oxymetazoline stimulated GHRH rather than inhibited somatostatin release. Pretreatment with CH-38083 (7,8-(methylenedioxy)-14-alpha-hydroxy-alloberban HCl, selective for alpha 2-adrenoceptors but not differentiating between alpha 2A and alpha 2B subtypes), prevented the plasma GH rise normally elicited by 1 microgram i.c.v. oxymetazoline. The alpha 2A- and alpha 1-selective adrenoceptor antagonist, WB-4101 (2-(2,6-dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane hydrochloride), prevented the GH rise normally induced by oxymetazoline while prazosin, the alpha 2B- and alpha 1-selective adrenoceptor antagonist, prolonged the elevation occurring in the control rats between 30 and 60 min after oxymetazoline injection. Since both prazosin and WB-4101 are alpha 1-adrenoceptor antagonists but differ in their action on alpha 2A and alpha 2B subtypes as well as in their action on oxymetazoline-induced GH secretion, the antagonist studies suggest that oxymetazoline stimulates GH release through activation of alpha 2A-adrenoceptors stimulatory to GHRH release, and not by an action through alpha 2B- or alpha 2C- or alpha 1-adrenoceptors. Since WB-4101 also antagonized clonidine action on GH release we also suggest that the major component may be the stimulation of the alpha 2A-adrenoceptors in the clonidine action on GH release.
Makara
G B
GB
Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.
Kiem
D T
DT
Vizi
E S
ES
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D004146:Dioxanes / Q000037:antagonists & inhibitors; D013007:Growth Hormone-Releasing Hormone / Q000097:blood / Q000378:metabolism; D007031:Hypothalamus / Q000737:chemistry / Q000378:metabolism*; D007276:Injections, Intraventricular; D008297:Male; D010109:Oxymetazoline / Q000494:pharmacology*; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000097:blood / Q000378:metabolism*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D001599:Berberine; C048886:7,8-(methylenedioxy)-14-hydroxyberbane; D013004:Somatostatin; D010109:Oxymetazoline; D013007:Growth Hormone-Releasing Hormone; C010654:(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane; D003000:Clonidine; D011224:Prazosin